CCR4 and synovial sarcoma: The chemokine receptor CCR4 is essential for cutaneous homing of helper T cells associated with Th2-mediated pathology, and is the target of mogamulizumab, a monoclonal antibody clinically effective in SS (47% overall response rate) [40].